| Name | Ozanimod |
| Description | Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis. |
| In vitro | In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation. [1] |
| In vivo | In vivo, Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses Clinicalal symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits Clinicalal and histological disease scores. In a Na?ve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 16.67 mg/mL (41.21 mM), Sonication is recommended.
Ethanol : 10 mg/mL (24.72 mM)
|
| Keywords | RPC1063 | RPC 1063 | neurosurgery | sphingosine 1-phosphate (S1P) | LPL Receptor | inhibit | Lysophospholipid Receptor | Ozanimod | Inhibitor | multiple sclerosis (MS) | S1P receptor subtypes 5 (S1P5) | S1P receptor subtypes 1 (S1P1) |
| Inhibitors Related | Tyloxapol | Ki16198 | Siponimod | MP-A08 | S1PR1 modulator 1 |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
